Lipitor Clone Lifts Ranbaxy Laboratories While Pfizer Inc. Bids Drug Goodbye

Published: May 11, 2012

Pfizer will no longer aggressively market Lipitor (atorvastatin), its former crown jewel and the most lucrative pharmaceutical product ever. At the same time, generic drug manufacturer Ranbaxy posted record revenue for the last business quarter, growth fueled largely by sales of generic atorvastatin in the United States.

Back to news